Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.
Author | |
---|---|
Abstract | :
The multicomponent meningococcal serogroup B vaccine (4CMenB) has been licensed in more than 35 countries. However, uncertainties remain about the lowest number of doses required to induce satisfactory, persistent immune responses. We did a systematic review and meta-analysis to provide quantitative estimates for the immunogenicity, persistence of immunogenicity, and safety of 4CMenB vaccine in children and adolescents. |
Year of Publication | :
2018
|
Journal | :
The Lancet. Infectious diseases
|
Date Published | :
2018
|
ISSN Number | :
1473-3099
|
DOI | :
10.1016/S1473-3099(18)30048-3
|
Short Title | :
Lancet Infect Dis
|
Download citation |